$Tenaya Therapeutics (TNYA.US)$ NEWS Tenaya Therapeutics to ...
NEWS
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics is demonstrating continuous innovation in core competencies at the ASGCT 27th Annual Meeting, showcasing its capabilities in genetic medicines for heart disease.
The company's pipeline includes two clinical-stage gene therapies for cardiomyopathies and research on gene therapy, gene editing, and cardiac cell regeneration using AAV as a delivery vehicle.
Tenaya's focus on capsid engineering, gene editing, and manufacturing process optimizations highlights its commitment to developing potentially curative therapies for heart disease.
The company's pipeline includes two clinical-stage gene therapies for cardiomyopathies and research on gene therapy, gene editing, and cardiac cell regeneration using AAV as a delivery vehicle.
Tenaya's focus on capsid engineering, gene editing, and manufacturing process optimizations highlights its commitment to developing potentially curative therapies for heart disease.
Despite the positive presentations at the ASGCT 27th Annual Meeting, Tenaya Therapeutics may face challenges in scaling up manufacturing processes and increasing yields for gene therapies.
The company may encounter hurdles in optimizing the safety and efficacy profiles of AAV-based gene therapies, which could impact the development and commercialization of precision heart medicines.
The company may encounter hurdles in optimizing the safety and efficacy profiles of AAV-based gene therapies, which could impact the development and commercialization of precision heart medicines.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
634Followers
74Following
4056Visitors
Follow